Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results

About this update from Simulations Plus, Inc.

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026. Third Quarter 2026 Financial Highlights (as compared to third quarter 2025) Total revenue increased 7% to $21.9 million Software revenue was flat at $12.6 million, representing 58% of total revenue Services revenue increased 20% to $9.3 million, representing 42% of total revenue Gross profit was $15.1 million and gross margin was 69%, compared to $13.0 million and 64% Net income of $3.6 million and diluted earnings per share of $0.18, compared to net loss of $67.3 million and diluted losses per share of $3.35 Adjusted EBITDA of $7.9 million, representing 36% of total revenue, compared to $7.4 million, representing 37% of total revenue Adjusted net income of $6.1 million and adjusted diluted EPS of $0.30 compared to adjusted net income of $9.0 million and adjusted diluted EPS of $0.45 Nine Months 2026 Financial Highlights (as compared to nine months 2025) Total revenue increased 5% to $64.6 million Software revenue decreased 2% to $36.1 million, representing 56% of total revenue Services revenue increased 14% to $28.5 million, representing 44% of total revenue Gross profit was $42.2 million and gross margin was 65%, compared to $36.4 million and 59% Net income of $8.8 million and diluted earnings per share of $0.43, compared to net loss of $64.0 million and diluted losses per share of $3.19 Adjusted EBITDA of $20.2 million, representing 31% of total revenue, compared to $18.5 million, representing 30% of total revenue Adjusted net income of $15.7 million and adjusted diluted EPS of $0.78, compared to $18.7 million and adjusted diluted EPS of $0.93 Management Commentary “We delivered solid third quarter results, with revenue increasing 7%, highlighted by strength in our services revenue, which grew 20%, while software revenue was flat year over year,” said Shawn O'Connor, Chief Executive Officer of Simulations Plus. “Our performance reflects the resilience of our business model and the value our solutions provide to clients across the drug development lifecycle.” “Subsequent to quarter end, on June 15, 2026, we entered into a definitive merger agreement to be acquired by affiliates of Altaris...

View stock analysis, news, and events for Simulations Plus, Inc.